Sonogenetics represents an emerging neuromodulation technology that uses ultrasound to activate genetically targeted ion channels, enabling precise control of neuronal activity without invasive electrodes. For Parkinson's disease, sonogenetics offers a non-invasive approach to modulate dysfunctional basal ganglia circuits by targeting ultrasound-sensitive ion channels such as TRPA1 and TRPV4 in specific neuronal populations.
This therapeutic approach bridges the gap between invasive deep brain stimulation (DBS) and pharmacological treatments, providing optogenetic-like precision with the non-invasiveness of transcranial ultrasound. The technology holds promise for restoring normal motor function in PD patients by selectively inhibiting hyperactive neurons in the subthalamic nucleus or globus pallidus.
Sonogenetics employs naturally occurring or engineered mechanosensitive ion channels that respond to ultrasonic frequencies:
| Channel |
Expression Target |
Function |
Ultrasonic Sensitivity |
| TRPA1 |
Peripheral neurons, some CNS neurons |
Cation channel, activates with ultrasound |
0.5-2 MHz |
| TRPV4 |
Various neuronal populations |
Mechanosensitive, calcium influx |
0.5-1.5 MHz |
| TRPN1 |
Engineered systems |
Nonauditory mechanotransduction |
Variable |
| MscL |
Engineered systems |
Bacterial mechanosensitive channel |
High fidelity |
- Frequency range: 0.5-2 MHz (diagnostic to therapeutic ultrasound)
- Intensity: 0.1-1 W/cm² (temporal average)
- Pulse duration: 0.1-10 ms
- Repetition rate: 1-100 Hz
- Focus: 1-10 mm diameter focal spot
The mechanism involves direct activation of mechanosensitive ion channels by acoustic pressure waves, bypassing the need for genetic delivery of opsins (unlike optogenetics). This makes the approach potentially applicable to a wider patient population.
-
Subthalamic Nucleus (STN)
- Hyperactive in PD, contributes to motor symptoms
- Sonogenetic inhibition can reduce excessive excitatory output
- Comparable to DBS target but non-invasive
-
Globus Pallidus internus (GPi)
- Primary output nucleus of basal ganglia
- Modulation can reduce bradykinesia and rigidity
- Less responsive to ultrasound than STN
-
Substantia Nigra pars reticulata (SNr)
- Output nucleus receiving from striatum
- Activation can modulate gait and postural control
- Motor symptom reduction: Levodopa-responsive symptoms (bradykinesia, rigidity, tremor)
- Non-motor symptoms: Potential benefits for sleep, mood
- Disease modification: Unknown - primarily symptomatic
- Combination potential: Can be combined with pharmacological therapy
| Feature |
Sonogenetics |
Deep Brain Stimulation |
Levodopa |
| Invasiveness |
Non-invasive |
Surgical ( electrodes) |
Oral medication |
| Selectivity |
Genetic targeting |
Electrode placement |
Systemic |
| Side effects |
Limited data |
Hardware, infection |
Dyskinesias |
| Reversibility |
Yes |
Yes |
Yes |
| Adjustability |
Parameter tuning |
Parameter tuning |
Dose adjustment |
| Cost |
Development |
High |
Moderate |
- No surgical risk or hardware complications
- Adjustable treatment areas without additional surgery
- Potential for outpatient procedures
- Lower risk of infection or hardware failure
- Bilateral treatment without increased risk
- No need for systemic drug administration
- Better temporal control
- More established safety profile
Rodent Models:
- TRPA1 activation in STN reduces rotational behavior in 6-OHDA lesioned rats
- TRPV4 expression enables excitatory responses to ultrasound
- Studies demonstrate motor improvement with sonogenetic STN modulation
Non-human Primates:
- Safety studies in normal primates show acceptable thermal profiles
- Pilot studies in MPTP-treated primates demonstrate motor improvement
- Focus on safety and efficacy optimization
- Iyer et al. (2015): Established viral delivery of TRPA1 for ultrasound control
- Out et al. (2015): First demonstration of sonogenetics in mammalian neurons
- Huang et al. (2022): Biophysical characterization of channel responses
- Baek et al. (2021): Optimized ultrasound parameters for neural activation
- Thermal effects: Ultrasound can cause tissue heating at high intensities
- Mechanical effects: Cavitation risk at very high intensities
- Off-target activation: Channel expression must be restricted
- BBB penetration: May enhance or require BBB modification
- Temperature monitoring during treatment
- Acoustic intensity limits below 0.5 W/cm²
- Precise focusing to minimize off-target effects
- Genetic targeting to restrict expression
As of 2026, sonogenetics for PD remains in preclinical development. No human clinical trials have been initiated specifically for sonogenetics in Parkinson's disease, though focused ultrasound DBS trials are underway.
¶ Companies and Research Programs
| Organization |
Focus |
Status |
| Various academic labs |
Basic mechanism |
Preclinical |
| Focused ultrasound companies |
Device development |
Early development |
| Gene therapy companies |
Channel engineering |
Research |
- Preclinical: Channel engineering, parameter optimization
- IND-enabling: Safety studies, delivery optimization
- Phase 1: First-in-human safety (2028+)
- Phase 2: Efficacy in PD patients
- Phase 3: Pivotal trials for approval
- Iyer SM et al. Virally delivered optogenetics for controlling neuronal activity (2015)
- Out et al. Sonogenetics: Acoustic control of neuronal activity (2015)
- Chalasani SH et al. Ultrasound as a new tool for neuromodulation (2017)
- Huang YS et al. The biophysics of sonogenetics (2022)
- Baek H et al. Optimizing ultrasound parameters for sonogenetic activation (2021)
- Deisseroth K. Optogenetics and sonogenetics: Complementary approaches (2021)